ArticleCell reports2023
IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive function.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Immune cells in keloids: mechanisms and potential treatments.Annals of medicine · 2026Review
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation.Molecular therapy. Advances · 2026Article
- Natural killer cells and regulatory T cells in aneurysmal subarachnoid hemorrhage in peripheral blood and cerebrospinal fluid - a pilot study.Fluids and barriers of the CNS · 2026Observational
- Programmable Semi-Interpenetrating Living Materials With Robust Stability for Versatile Bioremediation and Biotherapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From pathogenesis to therapy: the emerging role of regulatory T cells in amyotrophic lateral sclerosis.Journal of neuroinflammation · 2026Review
- The role of miRNAs in the development of Super-Tregs as a potential therapy for neurodegenerative diseases.Frontiers in immunology · 2026Review
- Acid-Responsive Zeolitic Imidazolate Framework-8 Core-Shell Nanovesicles Loaded with Interleukin-2 Nanoplatforms Selectively Expand Regulatory T Cells to Reconstruct Immunometabolic Homeostasis in Diabetic Neuropathy.Biomaterials research · 2026Article
- Kinase signaling in the control of regulatory T cell function: molecular mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Viral infections in solid organ transplant recipients: immunological principles and intervention strategies.American journal of translational research · 2026Review
- Integrative transcriptomic and proteomic profiling reveals altered thymocyte development and microenvironment remodeling during natural thymic atrophy.Frontiers in cell and developmental biology · 2026Article
- Exploring the Immunomodulatory Role of Forkhead Box Protein 3 (FOXP3) in the Pathophysiology of Neuropsychiatric Disorders.Molecular neurobiology · 2025Review
- Aberrant Subsets of Regulatory T Cells and their Correlations with Serum IL-2 in Patients with Rheumatoid Arthritis.Inflammation · 2025Article
- Immunodynamic Disruption in Sepsis: Mechanisms and Strategies for Personalized Immunomodulation.Biomedicines · 2025Review
- Mechanisms Underlying the Impact of Interleukin Family on Acute Kidney Injury: Pathogenesis, Progression, and Therapy.Research (Washington, D.C.) · 2025Review
- Advancements in Targeted Therapies for the Management of Crohn's Disease: A Comprehensive Review.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Hao SunUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Ho-Sup LeeUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Sarah Hyun-Ji KimUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Mikhael Fernandes de LimaUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Alexandre R GingrasUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Qinyi DuUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Wilma McLaughlinUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Jailail AblackUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Miguel A Lopez-RamirezUniversity of California San Diego School of Medicine, La Jolla, CA, USA; Department of Pharmacology, University of California, San Diego, La Jolla, La Jolla, CA, USA.
Frederic LagarrigueInstitute of Pharmacology and Structural Biology, Toulouse, France.
Zhichao FanUniversity of Connecticut School of Medicine, Farmington, CT, USA.
John T ChangUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Derek VanDykeDepartment of Chemical & Biomolecular Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Jamie B SpanglerDepartment of Chemical & Biomolecular Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Mark H GinsbergUniversity of California San Diego School of Medicine, La Jolla, CA, USA. Electronic address: mhginsberg@ucsd.edu.
University of California San Diego · USJohns Hopkins University · USInstitut de Pharmacologie et de Biologie Structurale · FRUniversity of Connecticut · US
Funding
The Hemostasis, Thrombosis, and Inflammation Models CoreP01HL151433 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark HOWARD Ginsberg · 2020 to 2026
$16.4MTraining In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1MDeconvoluting the Vascular AdhesomeR35HL139947 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2018 to 2024
$5.5MBlood Cells in Hemostasis and ThrombosisT32HL086344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2008 to 2023
$4.4MUCSD PRIDE Faculty Development Program in Cardiovascular SciencesR25HL145817 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Robert Scott Ross, Joann Trejo · 2019 to 2026
$3.3MMechanisms of hypoxia induced exacerbation of cerebral cavernous malformationsR01NS121070 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Miguel Alejandro Lopez-Ramirez · 2022 to 2026
$2.3MMolecular mechanism and preclinical translation of beta2 integrin auto-inhibition on neutrophil arrest and inflammationR01HL145454 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI FAN, ZHICHAO · 2019 to 2023
$2.1MImmunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7MNHLBI NIH HHS P01 HL151433NHLBI NIH HHS R01 HL145454NHLBI NIH HHS R25 HL145817NHLBI NIH HHS R35 HL139947NHLBI NIH HHS T32 HL007444NHLBI NIH HHS T32 HL086344NIBIB NIH HHS R01 EB029455NINDS NIH HHS R01 NS121070
Abstract
Canonical interleukin-2 (IL-2) signaling via the high-affinity CD25-containing IL-2 receptor-Janus kinase (JAK)1,3-signal transducer and activator of transcription 5 (STAT5) pathway is essential for development and maintenance of CD4
Indexed as
Encephalomyelitis, Autoimmune, ExperimentalT-Lymphocytes, RegulatoryAnimalsForkhead Transcription FactorsInterleukin-2Interleukin-2 Receptor alpha SubunitMiceReceptors, ChemokineReceptors, Interleukin-2Signal TransductionForkhead Transcription FactorsInterleukin-2Interleukin-2 Receptor alpha SubunitReceptors, ChemokineReceptors, Interleukin-2autoimmunityCD25chemokine receptorCP: Immunologyexperimental autoimmune encephalomyelitisheparan sulfateIL-2IL-2 receptorintegrinsregulatory T cellssignal transduction
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.